{"id":"https://openalex.org/W4392701040","doi":"https://doi.org/10.1158/1940-6207.c.6543894.v1","title":"Data from Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas","display_name":"Data from Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4392701040","doi":"https://doi.org/10.1158/1940-6207.c.6543894.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1940-6207.c.6543894.v1","doi":"https://doi.org/10.1158/1940-6207.c.6543894.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6543894.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1940-6207.c.6543894.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005918843","display_name":"Jason A. Zell","orcid":"https://orcid.org/0000-0003-2661-904X","observed_orcids":["https://orcid.org/0000-0003-2661-904X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason A. Zell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052553743","display_name":"Daniel Pelot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Pelot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019815608","display_name":"Wen\u2010Pin Chen","orcid":"https://orcid.org/0000-0002-0143-5642","observed_orcids":["https://orcid.org/0000-0002-0143-5642","https://orcid.org/0009-0001-1950-4634"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wen-Pin Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103071787","display_name":"Christine E. McLaren","orcid":"https://orcid.org/0000-0002-7932-9903","observed_orcids":["https://orcid.org/0000-0002-7932-9903"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christine E. McLaren","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108364106","display_name":"Eugene W. Gerner","orcid":"https://orcid.org/0000-0002-9906-8501","observed_orcids":["https://orcid.org/0000-0002-9906-8501"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eugene W. Gerner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5060872059","display_name":"Frank Louis Meyskens","orcid":"https://orcid.org/0000-0002-8827-4334","observed_orcids":["https://orcid.org/0000-0002-8827-4334"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frank L. Meyskens","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10552","display_name":"Colorectal Cancer Screening and Detection","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/difluoromethylornithine","display_name":"difluoromethylornithine","score":0.9779999852180481},{"id":"https://openalex.org/keywords/sulindac","display_name":"sulindac","score":0.9990000128746033},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.875},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.7570000290870667},{"id":"https://openalex.org/keywords/adverse-cardiovascular-events","display_name":"cardiovascular adverse events","score":0.7689999938011169},{"id":"https://openalex.org/keywords/chemoprevention","display_name":"chemoprevention","score":0.7319999933242798},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5109999775886536}],"concepts":[{"id":"https://openalex.org/C2776241388","wikidata":"https://www.wikidata.org/wiki/Q963093","display_name":"Sulindac","level":3,"score":0.908421516418457},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6791248321533203},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6124366521835327},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.5714375376701355},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47789156436920166},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.41663670539855957},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3246517777442932},{"id":"https://openalex.org/C2778484676","wikidata":"https://www.wikidata.org/wiki/Q20707196","display_name":"Nonsteroidal","level":2,"score":0.12686899304389954},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.10451808571815491},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.09520420432090759}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1940-6207.c.6543894.v1","doi":"https://doi.org/10.1158/1940-6207.c.6543894.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6543894.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1940-6207.c.6543894.v1","doi":"https://doi.org/10.1158/1940-6207.c.6543894.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1940-6207.c.6543894.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2137001235","https://openalex.org/W4362614785","https://openalex.org/W2971596758","https://openalex.org/W2097235831","https://openalex.org/W2171302210","https://openalex.org/W4392689862","https://openalex.org/W2081233507","https://openalex.org/W4362624991","https://openalex.org/W4385636856","https://openalex.org/W2147339810"],"abstract_inverted_index":{"Abstract":[0],"Nonsteroidal":[1],"anti-inflammatory":[2],"drugs":[3],"(NSAID)":[4],"have":[5,211],"been":[6],"associated":[7,29,194],"with":[8,30,125,153,195,197],"adverse":[9,32,44,134,162],"cardiovascular":[10],"(CV)":[11],"outcomes":[12,76],"in":[13,47,61,167],"cancer":[14,216],"prevention":[15,217],"and":[16,81,110,173,199],"other":[17],"clinical":[18,218],"trials.":[19,219],"A":[20,179],"recent":[21],"meta-analysis":[22],"suggested":[23],"that":[24],"baseline":[25,40,71,128,156,185,202],"CV":[26,33,41,45,72,74,87,129,135,157,163,181,192],"risk":[27,42,88,182,190],"is":[28],"NSAID-associated":[31],"events.":[34],"We":[35],"evaluated":[36],"the":[37,56,131,159,168],"effect":[38],"of":[39,52,98,133,161,191],"on":[43],"events":[46,136,164,193],"a":[48,126,154,200],"phase":[49],"III":[50],"trial":[51,96],"difluoromethylornithine":[53],"(DFMO)":[54],"plus":[55],"NSAID":[57],"sulindac":[58],"versus":[59],"placebo":[60,100,146,174],"preventing":[62],"colorectal":[63],"adenomas.":[64],"Trial":[65],"data":[66],"were":[67,77,90,165],"analyzed":[68],"to":[69],"determine":[70],"risk.":[73,208],"toxicity":[75],"then":[78],"assessed":[79],"overall":[80,95],"excluding":[82],"high":[83,107,119,127,155,180],"CV-risk":[84],"patients.":[85,122,150],"Baseline":[86],"scores":[89],"evenly":[91],"distributed":[92],"within":[93],"our":[94],"population":[97],"184":[99],"(low":[101,113],"risk,":[102,105,108,114,117,120,130,158],"27%;":[103],"moderate":[104,116],"34%;":[106],"39%)":[109],"191":[111],"DFMO/sulindac":[112,140,169],"30%;":[115],"29%;":[118],"41%)":[121],"In":[123],"patients":[124,152],"number":[132],"was":[137],"greater":[138],"among":[139,145],"(n":[141,147,170,175],"=":[142,148,171,176],"9)":[143],"than":[144],"3)":[149],"Excluding":[151],"numbers":[160],"similar":[166],"7)":[172],"6)":[177],"arms.":[178],"score":[183,203],"at":[184],"may":[186,204],"confer":[187],"an":[188],"increased":[189],"treatment":[196],"DFMO/sulindac,":[198],"low":[201],"not":[205],"increase":[206],"this":[207],"These":[209],"results":[210],"implications":[212],"for":[213],"future":[214],"NSAID-based":[215]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2024-03-13T00:00:00"}